Systematic literature review of the global burden of illness of mantle cell lymphoma
Neerav Monga, Constantine S. Tam(The Alfred Hospital), Peter O’Donovan(Genomics England), Joan Quigley(Imperial Consultants), Matthew S. Davids(Dana-Farber Cancer Institute), John O’Rourke(Imperial Consultants), Jamie Garside(Janssen (United Kingdom)), Lori Parisi(Janssen (United States)), Moira Hudson(Imperial Consultants), Christoph Tapprich(Janssen (Germany))
Cited by 14
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752